AmerisourceBergen / Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
OTLK is getting some commercial muscle once market approval is in:
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and AmerisourceBergen (NYSE: ABC), a global healthcare company and leader in specialty pharmaceutical distribution and services, announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).
AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as medical information and pharmacovigilance services in the United States. As Outlook Therapeutics moves toward a potential launch in the United States, and if ONS-5010 is approved by FDA, AmerisourceBergen’s commercialization support will expand to include additional services, such as patient services and field solutions.
“Following our recent Biologics License Application (BLA) submission, entering a relationship with AmerisourceBergen for ONS-5010 is a critical step in the next phase of our pre-commercial strategy execution,” commented C. Russell Trenary, III, President and CEO of Outlook Therapeutics. “AmerisourceBergen is the preeminent leader in specialty pharma distribution, which will provide expansive reach and access to the vast majority of anti-VEGF providers. This is expected to significantly enhance our commercial reach. Together, we believe we will be in a position to significantly upgrade treatment options for people living with wet AMD.”
“We are thrilled to support Outlook Therapeutics for their pre-commercial launch preparations and, pending FDA approval, plan to leverage our portfolio of commercialization solutions to help them maximize commercial success and increase patient access,” said Willis Chandler, President of Global Pharma Services at AmerisourceBergen. “We are uniquely positioned to deliver support across the product lifecycle to meet our partners’ specific needs and help them achieve the outcomes they desire. We look forward to continuing to expand our support—both in the U.S. and key markets worldwide—over time.”
As the exclusive distribution partner to more than 65,000 community practices nationwide, AmerisourceBergen distributes specialty care products to community practices, such as retinal, eye surgery and ophthalmology practices. If ONS-5010 receives approval, AmerisourceBergen’s Besse Medical, one of the largest specialty pharmaceutical distributors to retina specialists, will work to ensure providers across the United States have efficient access to the product. As part of the agreement, AmerisourceBergen’s ICS affiliate, a leader in outsourced logistics and distribution services, will provide distribution support, including cold chain storage, via its network of facilities nationwide. Innomar Strategies, a leading service provider for biopharma companies in Canada and a part of AmerisourceBergen, will deliver pharmacovigilance and medical information services for ONS-5010 in the United States.
Through the agreement with AmerisourceBergen, Outlook Therapeutics expects to significantly increase market access and efficient distribution of ONS-5010, if approved by the FDA. Moreover, working with AmerisourceBergen will help to provide Outlook Therapeutics with an accelerated pathway to deliver a high-quality customer experience to retina specialists.
Outlook Therapeutics is also exploring a relationship with AmerisourceBergen to support the launch of ONS-5010 in international markets. AmerisourceBergen expanded its global distribution capabilities in 2021 with the acquisition of Alliance Healthcare, a leading wholesaler of healthcare products in Europe.
AI
